Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses

(2008) Y. K. Shue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment ofClostridium difficileInfection

(2008) Dale N. Gerding et al.   CLINICAL INFECTIOUS DISEASES

Comparison of Clinical and Microbiological Response to Treatment ofClostridium difficile–Associated Disease with Metronidazole and Vancomycin

(2008) Wafa N. Al‐Nassir et al.   CLINICAL INFECTIOUS DISEASES

OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review

(2008) Michael Gerber et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS